These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19615069)

  • 21. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
    Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
    Schädlich PK; Huppertz E; Brecht JG
    Pharmacoeconomics; 1998 Dec; 14(6):653-69. PubMed ID: 10346417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of genotype testing for primary resistance in Brazil.
    Luz PM; Morris BL; Grinsztejn B; Freedberg KA; Veloso VG; Walensky RP; Losina E; Nakamura YM; Girouard MP; Sax PE; Struchiner CJ; Paltiel AD
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):152-61. PubMed ID: 25415289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings.
    Carvalho N; Hoque ME; Oliver VL; Byrne A; Kermode M; Lambert P; McIntosh MP; Morgan A
    BMC Med; 2020 Jul; 18(1):201. PubMed ID: 32718336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
    Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
    BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
    Vrdoljak E; Sekerija M; Plestina S; Belac Lovasic I; Katalinic Jankovic V; Garattini L; Bobinac A; Voncina L
    Eur J Health Econ; 2021 Apr; 22(3):393-403. PubMed ID: 33438133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of different strategies for screening and treatment of
    Wikman-Jorgensen PE; Llenas-Garcia J; Shedrawy J; Gascon J; Muñoz J; Bisoffi Z; Requena-Mendez A
    BMJ Glob Health; 2020 May; 5(5):. PubMed ID: 32461226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis.
    Beard SM; Holmes M; Price C; Majeed AW
    Ann Surg; 2000 Dec; 232(6):763-76. PubMed ID: 11088071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.